Dr. Ladanyi Discusses Research on RRAS and RRAS2 Hotspot Mutations
Martin Reck, MD, PhD, on KEYNOTE-799, LAURA, and the Future of Treatment for Stage III NSCLC
HARMONi-2: Dr. Liu Discusses Implications, Unanswered Questions, and Next Steps
Exploratory Analysis of ADRIATIC Sheds Light on Metastases Outcomes With Durvalumab Consolidation in LS-SCLC
KEYNOTE-799 Final Analysis Shows Regimen Has ‘Sustainable Efficacy’ in NSCLC
Subcutaneous Pembrolizumab Shows Non-inferiority to IV Pembrolizumab for Metastatic NSCLC